209 related articles for article (PubMed ID: 27718310)
1. Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia.
de de la Fuente Garcia I; Coïc L; Leclerc JM; Laverdière C; Rousseau C; Ovetchkine P; Tapiéro B
Pediatr Blood Cancer; 2017 Feb; 64(2):315-320. PubMed ID: 27718310
[TBL] [Abstract][Full Text] [Related]
2. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens.
Nilsson A; De Milito A; Engström P; Nordin M; Narita M; Grillner L; Chiodi F; Björk O
Pediatrics; 2002 Jun; 109(6):e91. PubMed ID: 12042585
[TBL] [Abstract][Full Text] [Related]
3. Revaccination of children after completion of standard chemotherapy for acute leukemia.
Patel SR; Ortín M; Cohen BJ; Borrow R; Irving D; Sheldon J; Heath PT
Clin Infect Dis; 2007 Mar; 44(5):635-42. PubMed ID: 17278052
[TBL] [Abstract][Full Text] [Related]
4. Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination.
Zengin E; Sarper N
Pediatr Blood Cancer; 2009 Dec; 53(6):967-72. PubMed ID: 19544393
[TBL] [Abstract][Full Text] [Related]
5. Assessment of immune response following immunization with DTP/Td and MMR vaccines in children treated for acute lymphoblastic leukemia.
Koochakzadeh L; Khosravi MH; Pourakbari B; Hosseinverdi S; Aghamohammadi A; Rezaei N
Pediatr Hematol Oncol; 2014 Oct; 31(7):656-63. PubMed ID: 25007393
[TBL] [Abstract][Full Text] [Related]
6. Antibody response to vaccination after haematopoietic cell transplantation in children using a reduced dose schedule-A retrospective cohort study.
Jensen L; Poulsen A; Nygaard U; Scheike T; Riis MS; Pedersen FK; Heilmann C
Pediatr Transplant; 2020 Feb; 24(1):e13599. PubMed ID: 31617270
[TBL] [Abstract][Full Text] [Related]
7. Childhood vaccinations and risk of acute lymphoblastic leukaemia in children.
Søegaard SH; Rostgaard K; Schmiegelow K; Kamper-Jørgensen M; Hargreave M; Hjalgrim H; Hviid A
Int J Epidemiol; 2017 Jun; 46(3):905-913. PubMed ID: 28431124
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.
Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M
Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966
[TBL] [Abstract][Full Text] [Related]
9. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination.
Fouda AE; Kandil SM; Boujettif F; Salama YS; Fayea NY
Hematology; 2018 Oct; 23(9):590-595. PubMed ID: 29614919
[TBL] [Abstract][Full Text] [Related]
11. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
12. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b.
Ek T; Mellander L; Hahn-Zoric M; Abrahamsson J
J Pediatr Hematol Oncol; 2004 Nov; 26(11):727-34. PubMed ID: 15543007
[TBL] [Abstract][Full Text] [Related]
13. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
15. Haemophilus influenzae type B in an immunocompetent, fully vaccinated ALL survivor.
Nevin J; Kanter Washko J; Arnold J
Pediatrics; 2013 May; 131(5):e1639-42. PubMed ID: 23589809
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
[TBL] [Abstract][Full Text] [Related]
17. Immunization response varies with intensity of acute lymphoblastic leukemia therapy.
Ridgway D; Wolff LJ; Deforest A
Am J Dis Child; 1991 Aug; 145(8):887-91. PubMed ID: 1858726
[TBL] [Abstract][Full Text] [Related]
18. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
[TBL] [Abstract][Full Text] [Related]
19. Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer.
Bochennek K; Allwinn R; Langer R; Becker M; Keppler OT; Klingebiel T; Lehrnbecher T
Vaccine; 2014 Jun; 32(27):3357-61. PubMed ID: 24793952
[TBL] [Abstract][Full Text] [Related]
20. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer.
Reinhardt D; Houliara K; Pekrun A; Lakomek M; Krone B
Scand J Infect Dis; 2003; 35(11-12):851-7. PubMed ID: 14723361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
